Endogenous erythropoietin and erythropoietin receptors in colorectal cancer; can we answer the questions?

详细信息    查看全文

• 作者：Aleksandar Čubranić^a ; ^{acubrani@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; Renata Dobrila-Dintinjana^b ; Arnela Redžović^b ; Marijan Dintinjana^c ; Du&scaron ; ka Petranović^d ; Marin Golčić^b
• 关键词：CEA ; carcinoembrional tumor marker ; CRC ; colorectal carcinoma ; EMT ; epithelial-mesenchymal transition ; Epo ; erythropoietin Epo ; EpoR ; erythropoietin recepotors ; HCC ; hepatocellular carcinoma ; HIF-1α ; hypoxia inducible factor 1 alpha ; MV ; mosaic vessels ; TNM ; tumor ; node ; metastasis ; VEGF ; vascular endothelial growth factor
• 刊名：Medical Hypotheses
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：96
• 期：Complete
• 页码：16-19
• 全文大小：1399 K

文摘

Erythropoietin (Epo) is glycoprotein hormone which binds on erythropoietin receptors (EpoR) promoting proliferation and differentiation. Studies have shown that EpoR, apart from erythrocyte precursors, is expressed on no hematopoietic tissue and various tumor cells.

Despite the progress in modern medicine, colorectal carcinoma (CRC) is still the leading cause of increased morbidity and mortality between oncology patients worldwide. Its precursors are benign villous adenomas, which in certain percentage progress to cancer. Anemia of chronic disease is common finding in CRC patients. Some of them are treated with Epo. Epo/EpoR seems to correlate with tumor progression and metastasizing. Therefore, the identification of at-risk group remains a clinical challenge. Vascular endothelial growth factor (VEGF) is a signal protein that stimulates angiogenesis and concentration of VEGF is positive correlated with tumor growth in numerous tumors.

The importance of Epo in tumor pathogenesis has led to a growing interest in the potential prognostic value. By our point of view there are many open questions about role of Epo/EpoR in CRC.